Rohto Eye Drops Recall Covers 12.46 Million Bottles Over Sterility Failure

Roughly 12.46 million bottles of over-the-counter cooling eye drops have been withdrawn from United States distribution because the manufacturer could not certify that the product was sterile. The Food and Drug Administration classified the action as Class II on July 23, nine days after Rohto-Mentholatum (Vietnam) Co., Ltd. began pulling the stock, and national coverage of the enforcement report followed on July 29 and 30.

Counts published by different outlets diverge slightly because of packaging. AOL and Yahoo News, citing the FDA enforcement database, reported 12,460,649 bottles. Television newsrooms including WSB-TV in Atlanta and ABC10 counted the same action at 11,960,623 cartons, a figure that treats a twin pack as one unit. Whichever unit is used, the Rohto eye drops recall ranks among the largest ophthalmic withdrawals recorded in the country in recent years.

Recall Scope and Timeline

According to the FDA enforcement listing summarized by News4Jax, the voluntary action began on July 14, when Rohto-Mentholatum (Vietnam) Co., Ltd. notified the agency. The FDA completed its classification review on July 23 and assigned Class II status. Distribution was nationwide, handled by The Mentholatum Company, based in Orchard Park, New York. Rohto is a Japanese brand, and the recalled units were produced at the company's Vietnamese facility.

The action reached the public through the agency's weekly enforcement report rather than through a company announcement. WFLA, part of the Nexstar group that circulated the story nationally, reported that no press release carrying consumer instructions accompanied the listing and that the manufacturer did not respond to requests for comment. That distinction matters in practice: FDA posts company announcements on a separate recalls and safety alerts page that consumers are far more likely to encounter than the enforcement database.

The stated reason across every affected product line is identical: lack of assurance of sterility. That phrase describes a documentation and process failure rather than a confirmed finding of bacteria or fungi in finished goods. No illnesses had been reported in connection with the Rohto eye drops recall as of the enforcement report, according to reporting by Boston 25 News and ABC10.

Expiration dates on the affected lots run from July 2026 through February 2029. That range matters more than the raw volume figure. Product with a 2028 or 2029 expiry was manufactured recently and is likely to be sitting on retail shelves or in household medicine cabinets rather than already consumed.

Products and Volumes Under Withdrawal

News4Jax counted eight separate product entries in the enforcement listing. Brand variants named across coverage from ABC10, WTHR and Eyes On Eyecare include Rohto Cooling Eye Drops ALL-IN-ONE, Max Strength in both single and twin pack formats, Optic Glow, Digi Eye, Dry Aid, Cool Relief, and the base Cooling Drops line.

Volume is heavily concentrated in one variant. ABC10 reported 6,076,306 cartons of Max Strength in single format, plus 499,673 cartons of the Max Strength twin pack. Optic Glow accounted for 1,278,457 cartons and ALL-IN-ONE for 1,033,266 cartons. Cool Relief adds 2,910,148 cartons, the second largest entry in the listing, while Dry Aid accounts for 97,201 cartons plus 353 twin packs and Digi Eye for 65,219 cartons, the smallest line covered. MedShadow Foundation, reviewing the same enforcement entries, reported that the affected units are packed in 0.34 and 0.4 fluid ounce bottles, the standard retail sizes for the brand.

Retail exposure spans mass grocery and direct-to-consumer channels. Eyes On Eyecare identified Kroger locations and the brand's own online shop among the outlets where affected product was sold, and coverage described the withdrawal as nationwide. Consumers cannot identify affected stock by product name alone, because only specific lots are covered. Matching the UPC and lot number printed on the carton against the FDA list is the only reliable check.

Class II Sits Below Life-Threatening Territory

News4Jax quoted the agency's standard definition: Class II applies when products "may cause temporary or reversible adverse health consequences, or the probability of serious harm is considered remote." Class I, the tier above, is reserved for situations where exposure carries a reasonable probability of serious injury or death. Class III covers violations unlikely to cause any adverse reaction.

That gradation explains why the Rohto eye drops recall has not triggered the kind of public health alert that accompanied earlier ophthalmic contamination events. The manufacturer flagged a gap in sterility assurance, not a positive microbial test. Regulators treat the two differently, though both trigger removal from commerce.

Class II status also shapes retailer obligations. Stores are expected to remove affected lots and honor returns, but the FDA does not require the kind of direct consumer notification campaign that a Class I event would prompt. That places more of the burden on shoppers to check their own inventory.

Sterility Assurance Carries Weight in Ophthalmics

Eye drops occupy an unusual regulatory position. They are sold over the counter alongside cosmetics and vitamins, yet they must meet sterility standards closer to injectable drugs. The ocular surface has limited immune defense, the cornea is avascular, and a bacterial or fungal infection introduced through a dropper tip can progress to corneal ulceration or endophthalmitis before a patient seeks care.

Multi-dose bottles compound the problem. Every use exposes the dispensing tip to the eyelid, the lashes and the surrounding skin. Preservative systems are designed to control that reintroduction. When a manufacturer cannot demonstrate sterility at release, the preservative system is the only remaining barrier, and regulators are unwilling to rely on it alone.

Precedent from the 2023 Artificial Tears Outbreak

Recent history explains the caution. In February 2023 the FDA warned consumers not to use EzriCare Artificial Tears after the Centers for Disease Control and Prevention linked the product to an extensively drug-resistant strain of Pseudomonas aeruginosa carrying Verona integron-mediated metallo-beta-lactamase and Guiana extended-spectrum beta-lactamase resistance genes. CDC health advisories tracked 55 patients across 12 states by the end of January 2023, rising to 81 patients in 18 states by mid-May, with deaths and permanent vision loss among the outcomes.

The FDA's inspection findings in that case cited current good manufacturing practice violations including inadequate microbial testing, formulation of an ophthalmic drug in multi-use bottles without appropriate preservative, and deficient tamper-evident packaging controls. The strain involved had never been documented in the United States before that outbreak. Agency scrutiny of imported ophthalmic manufacturing intensified afterward, and the Rohto eye drops recall reflects the lower tolerance that followed.

Outcomes in that outbreak were severe. Writing for The Conversation, C. Michael White, distinguished professor of pharmacy practice at the University of Connecticut, put the toll at 81 people across 18 states, of whom 14 lost vision, four had an eye surgically removed and four died. Enforcement did not stop at one importer. Kilitch Healthcare India Limited recalled 27 eye drop products in late 2023 after FDA investigators found insanitary conditions and positive bacterial results from environmental sampling of critical production areas, with the agency recommending recall of all lots on October 25, 2023. Accounts of that inspection describe employees working barefoot on the manufacturing floor and product that had failed sterility testing being released anyway.

Ophthalmic Withdrawals Since May 2025

Two other large actions bracket this one. In May 2025 the FDA classified a recall of five ophthalmic solutions traced to BRS Analytical Service LLC as Class II, covering more than 75,000 cases shipped between May 26, 2023 and April 21, 2025. Today.com and Healio identified the products as artificial tears, carboxymethylcellulose sodium gel and solution, lubricant eye drops and polyvinyl alcohol solution, pulled after an FDA audit documented current good manufacturing practice deviations and, in the enforcement language used again this July, lack of assurance of sterility.

Ten months later came a bigger one. White documented a March 3, 2026 recall of 3.1 million bottles from K.C. Pharmaceuticals, spanning eight products sold under 12 brand names including Walgreens, CVS and Kroger labels, with expiration dates running from April 30, 2026 to October 31, 2026. He noted that the FDA had already issued that company a warning letter over sterility procedures on August 3, 2023, and that the agency had inspected over-the-counter eye drop manufacturers only a few times before the 2023 outbreak forced the issue.

His framing of the clinical stakes is direct: "Using nonsterile eye drops that harbor bacteria and fungus can cause eye infections, which can become severe because the immune system has a hard time accessing the eyeball and fighting the microbes." Counting bottles rather than cartons, the Rohto eye drops recall is roughly four times the size of the K.C. Pharmaceuticals action from March.

Inspection Record at the Vietnam Plant

ProPublica's Rx Inspector database, which compiles FDA inspection outcomes facility by facility, lists six inspections of Rohto-Mentholatum (Vietnam) Co., Ltd. The first, on May 15, 2012, ended in what the agency classified as an unacceptable state of compliance, carrying 13 citations that included deficient aseptic processing areas and inadequate sampling procedures.

Consequences followed. The site was placed under an import ban on August 26, 2013, blocking entry of its product to the United States, and the restriction stayed in force until October 21, 2016. Three later inspections, on April 14, 2015, March 16, 2018 and November 1, 2019, each recorded problems the agency judged the company could correct voluntarily, without a warning letter or import action.

None of that history has been linked by regulators to the sterility assurance gap behind the current withdrawal, and the database shows no published enforcement action against the plant since 2019. It does set the Rohto eye drops recall against a compliance file the agency has opened before.

Foreign Site Oversight After the 2025 Policy Shift

Where a plant sits determines how often an inspector arrives unannounced. On May 6, 2025 the FDA announced an expansion of surprise inspections at foreign facilities making food, medicines and other medical products for the American market. Commissioner Martin Makary, quoted in the agency announcement, said: "For too long, foreign companies have enjoyed a double standard," receiving advance notice that domestic manufacturers do not get.

Legal analyses filled in the arithmetic. Cooley noted that foreign establishments had historically received up to 12 weeks of advance notice, and that India and China together account for more than one third of the foreign establishments supplying the US market. McGuireWoods reported that in fiscal 2023 nearly 90 percent of FDA foreign inspections were preannounced, yet investigators still documented serious deficiencies abroad at more than twice the rate found at domestic sites.

Execution is the unresolved part. The announcement followed a May 5, 2025 executive order on domestic pharmaceutical production and set an August 3, 2025 deadline for the agency to build an improved risk-based inspection regime. Firm analyses flagged the same constraint: a long-standing shortage of investigators available for foreign travel, compounded by staff reductions at the agency, limits how fast unannounced visits can scale. The pilot that preceded the expansion covered India and China. Vietnam was not part of it.

Consumer Steps and Reporting Channels

Guidance reported consistently across outlets is straightforward. Locate the UPC and lot number on the carton or bottle, compare them against the FDA enforcement listing at accessdata.fda.gov, and stop using any product that matches. Affected units should be discarded or returned to the point of purchase.

Anyone who has used product covered by the Rohto eye drops recall and develops symptoms should contact a clinician rather than wait. Pain, redness that worsens rather than improves, discharge, light sensitivity and any change in vision warrant same-day evaluation. Contact lens wearers face elevated risk because lenses extend contact time between the ocular surface and any contaminant.

Adverse events can be reported through the FDA's MedWatch program at fda.gov/safety/medwatch or by telephone at 1-800-FDA-1088. Reports feed the surveillance system that determines whether a classification is revised upward. The absence of illness reports at classification does not close the question, because ophthalmic infections are frequently attributed to contact lens hygiene or environmental exposure rather than to a specific product.

Gaps Left in the Public Record

Several elements of the case remain undisclosed in public filings. Neither the manufacturer nor the agency has published the specific process deviation that produced the sterility assurance gap, whether it involved environmental monitoring, media fill validation, container closure integrity or batch record completeness. The date range on affected lots suggests the issue persisted across an extended production window rather than a single campaign.

Recovery rates are the other unknown. Withdrawals of this size rarely retrieve a large share of units already sold, and product with a 2029 expiry can remain in circulation for years. The volume involved in the Rohto eye drops recall means residual stock will outlast most news coverage of it.

For the broader category, the episode reinforces a pattern regulators have been tracking since 2023. Over-the-counter ophthalmic products are manufactured on thin margins, frequently offshore, and sold through channels that make lot-level traceability difficult once product reaches a consumer. Each successive Rohto eye drops recall notice and similar action shifts more of the verification burden onto the FDA enforcement database, a resource most shoppers have never opened.

Next Checkpoints in the Case

The enforcement listing stays open until the FDA records the action as terminated, a status the agency assigns only once a recalling firm documents that retrieval is finished, so the classification page remains the reference point for lot checking into the autumn. Stock carrying July 2026 expiry dates clears shelves on its own within weeks. Product dated 2028 and 2029 does not, and it represents the bulk of the volume.

Public documentation would sharpen the picture. Publication of a Form 483 or a warning letter from any recent inspection of the Vietnamese plant would name the specific deviation behind the sterility finding, and an upward revision of the Class II designation would follow if MedWatch reports begin to accumulate. Neither had appeared as of July 31.

Beyond this file, the test is whether the unannounced inspection program announced in May 2025 reaches plants outside the India and China pilot before the next sterility finding rather than after it. On the record so far, the sequence has run the other way: a recall lands, coverage follows, and the inspection history surfaces only once reporters go looking for it.